The 9-valent HPV vaccine (Gardasil-9; manufactured by Merck) has taken the place of
the quadrivalent HPV vaccine (Gardasil) in the U.S. HPV-9 is available in 0.5 mL single-dose
vials in packs of 10, according to Merck.
On or before Oct. 31, Gardasil will no longer be available for purchase directly from
the company, according to a Merck spokesperson. Wholesalers and physician distributors
may have inventory remaining, which may continue to be purchased until their supply
is depleted. Merck will continue to manufacture Gardasil for use in markets outside
The Vaccines for Children program already has transitioned to the 9-valent HPV vaccine.
The 2016 Immunization Schedule recommends three doses of HPV vaccine for 11- to 12-year-old
boys and girls.